KRIBIOLISA™ Bevacizumab (AVASTIN) ELISA
₹34,000.00
Enzyme Immunoassay for the estimation of Bevacuzimab (AVASTIN) in serum and plasma.
Key features:
1. Developed using highly specific monoclonal anti-idiotypic antibodies in a sandwich assay format
2. Validated as per international bioassay validation guidelines
3. Recovery: 80-120%
4. Precision CV <10%
Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells
Powered by BiozDescription
Background:
Bevacizumab is a recombinant Human IgG kappa monoclonal antibody specific for all human vascular endothelial growth factor A (VEGF-A) isoforms. An angiogenesis inhibitor, it acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumor blood vessels and thus limits the blood supply to tumor tissues. These effects also lower tissue interstitial pressure, increase vascular permeability, may increase delivery of chemotherapeutic agents, and favor apoptosis of tumor endothelial cells. Additionally, Bevacizumab binds to and neutralizes all human VEGF-A isoforms an bioactive proteolytic fragments, but not mouse or rat VEGF.
Intended Use:
For Estimation of Bevacuzimab (AVASTIN) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Bevacizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Bevacizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Bevacizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Bevacizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!
Additional information
| Specificity | 80% – 120% to Bevacuzimab (AVASTIN)ELISA |
|---|---|
| Cross Reactivity | < 0.5% cross-reactivity observed with related biomarker. |
| Interference | No significant interference observed with available related molecules. |
| Regulatory Status | Research Use Only |
| Research Area | Biosimilars / Therapeutic Drug Monitoring |
| Entez Gene ID | ABP 215 Human |
| Storage Temprature | Store the unopened product at 2-8 Degree Celcius. Concentrated detection conjugate should be stored at -20 Degree Celcius. Do not use past expiration date. |
| Shipping Temperature | 2-8 Degree Celcius. Concentrated detection conjugate ship at -20 Degree Celcius in a second box. Freight applicable for both. |
| ELISA Type | Direct Sandwich Assay |
| Validation | The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer to the IFU for more details. |
| Disclaimer | Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only. |
| Long Name | Protein Based Therapies – Monoclonal Antibody |